公开(公告)号：US20180193475A1

公开(公告)日：2018-07-12

申请号：US15329818

申请日：2015-07-27

Applicant: Novartis AG

Inventor： Tinya ABRAMS ,  Steven Bruce COHEN ,  Dylan DANIEL ,  Catrin FINNER ,  Bernhard Hubert GEIERSTANGER ,  Thomas HUBER ,  William MALLET ,  Matthew John MEYER ,  Weijia OU ,  Siew Ho SCHLEYER ,  Kathrin Ulrike TISSOT-DAGUETTE

IPC: A61K47/68 ,  A61K39/395 ,  C07K16/28 ,  A61P35/02

CPC classification number: A61K47/6803 ,  A61K39/39558 ,  A61K47/6849 ,  A61K49/00 ,  A61K51/103 ,  A61K51/1093 ,  A61K2039/505 ,  A61K2039/545 ,  A61P35/02 ,  C07K16/2803 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

公开(公告)号：US20220008426A1

公开(公告)日：2022-01-13

申请号：US17191205

申请日：2021-03-03

Applicant: Novartis AG

Inventor： Giordano CAPONIGRO ,  Vesselina COOKE ,  Matthew John MEYER ,  Darrin STUART

IPC: A61K31/5377 ,  A61P35/00 ,  A61K31/4965

Abstract: The present invention relates to a combination treatment which comprises (a) at least one ERK inhibitor preferably Compound B as described herein, and (b) a c-RAF inhibitor or a pharmaceutically acceptable salt thereof, preferably Compound A, which may be combined into a single pharmaceutical composition or prepared for separate or sequential administration. It includes a c-RAF inhibitor and an ERK inhibitor prepared for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly an advanced solid tumor that harbors a Mitogen-activated protein kinase (MAPK) alteration, and includes methods of using these compounds in combination as well as a commercial package comprising such combination.

公开(公告)号：US20210040205A1

公开(公告)日：2021-02-11

申请号：US16758748

申请日：2018-10-23

Applicant: NOVARTIS AG

Inventor： Sunyoung JANG ,  Haihui LU ,  Matthew John MEYER ,  Ryan MOLONY ,  Karrie WONG

IPC: C07K16/28 ,  A61K47/68 ,  A61K45/06

Abstract: The present disclosure relates to anti-CD32b antibody molecules which selectively bind human CD32b. Also provided herein are compositions comprising anti-CD32b antibody molecules in combination with other compounds, and methods of using the combinations to treat subject with cancer.

公开(公告)号：US20170198040A1

公开(公告)日：2017-07-13

申请号：US15382251

申请日：2016-12-16

Applicant: Novartis AG

Inventor： Nicole BALKE ,  Thomas CALZASCIA ,  Stefan EWERT ,  Alan HARRIS ,  Heather Adkins HUET ,  Isabelle ISNARDI ,  Haihui LU ,  Matthew John MEYER ,  Nicholas WILSON ,  Fangmin WU

IPC: C07K16/28 ,  A61K45/06

CPC classification number: C07K16/2803 ,  A61K39/395 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/541 ,  A61K2039/545 ,  C07K16/28 ,  C07K16/283 ,  C07K16/2887 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to isolated antibodies and antigen-binding fragments thereof which selectively bind human CD32b. Also provided herein are compositions comprising the antibodies or antigen-binding fragments thereof, methods of using the antibodies or antigen-binding fragments thereof, and methods of making the antibodies or antigen-binding fragments thereof.